Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Willow Biosciences Inc T.WLLW

Alternate Symbol(s):  CANSF

Willow Biosciences Inc. is a Canada-based biotechnology company. The Company develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Its FutureGrown biotechnology platform allows production with sustainability at its core. Its commercial product, Cannabigerol CBG, which is a cannabinoid that has anti-microbial... see more

TSX:WLLW - Post Discussion

Willow Biosciences Inc > Cannabinoid Manufacturing Yield
View:
Post by Bullknit101 on Jun 17, 2021 9:29pm

Cannabinoid Manufacturing Yield

I was considering buying some Willow but still heavily into InMed that has a process to produce any cannabinoid API grade and GMP. Would be interested to know the production yield is for Willow CBG if anyone knows: https://finance.yahoo.com/news/inmed-pharmaceuticals-increases-cannabinoid-yield-113000409.html
Comment by VPAThinker on Jun 18, 2021 4:33pm
Willow CEO has stated that they will not likely publicly disclose their production yields. Of course that might change if they feel it somehow becomes a relevent comparison. Really, they key metric will be the sale price vs. the overall cost to produce. If for some reason it took more volume to produce each gram, but the cost is half, the comparison is moot. That said, I took at look at Inmed and ...more  
Comment by Bullknit101 on Jun 19, 2021 8:03am
Thanks for your comments- makes sense. I hope both companies are successful in the end.
Comment by lscfa on Jun 19, 2021 8:54am
Slide 4:  Assumes average dry flower yield of 10% CBDa (w/w) or CBDa production of 5 g/L in 100,000L fermentation facility. https://www.willowbio.com/img/willow-corporate-update.pdf     
Comment by lscfa on Jun 19, 2021 9:06am
Slide 15:    Commercial titer target of 3-5 g/L necessary for COGS targets is a realistic objective and will be the key optimization driver
Comment by VPAThinker on Jun 21, 2021 9:55am
Yes, the corp presentation has a lot of great info, as does this interview: https://www.youtube.com/watch?v=0JCvX6E9aL4 I think it is in that interview where he mentions that they will not report exact yields but does give some very good numbers on what they can produce.
Comment by Bullknit101 on Jun 21, 2021 11:39am
Maybe there will be room for optimization using Integrasyn for CBG production: https://youtu.be/ha871PWI_WQ
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities